| __timestamp | Amneal Pharmaceuticals, Inc. | Amphastar Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 785623000 | 210461000 |
| Thursday, January 1, 2015 | 866280000 | 251519000 |
| Friday, January 1, 2016 | 1018225000 | 255165000 |
| Sunday, January 1, 2017 | 1033654000 | 240175000 |
| Monday, January 1, 2018 | 1662991000 | 294666000 |
| Tuesday, January 1, 2019 | 1626373000 | 322357000 |
| Wednesday, January 1, 2020 | 1992523000 | 349846000 |
| Friday, January 1, 2021 | 2093669000 | 437768000 |
| Saturday, January 1, 2022 | 2212304000 | 498987000 |
| Sunday, January 1, 2023 | 2393607000 | 644395000 |
Unlocking the unknown
In the competitive landscape of pharmaceuticals, revenue growth is a key indicator of success. Over the past decade, Amneal Pharmaceuticals, Inc. has consistently outpaced Amphastar Pharmaceuticals, Inc. in annual revenue. From 2014 to 2023, Amneal's revenue surged by over 200%, reaching approximately $2.4 billion in 2023. In contrast, Amphastar's revenue grew by about 200% as well, but only reached around $644 million in the same year.
Amneal's strategic acquisitions and diverse product portfolio have been pivotal in its revenue growth, especially noticeable in 2018 when their revenue jumped by 60% compared to the previous year. Meanwhile, Amphastar has shown steady growth, with a notable 29% increase in 2023, driven by its focus on niche markets and innovative products.
As the pharmaceutical industry continues to evolve, these two companies exemplify different paths to growth and success.
Revenue Showdown: Eli Lilly and Company vs Amphastar Pharmaceuticals, Inc.
Gilead Sciences, Inc. vs Amneal Pharmaceuticals, Inc.: Examining Key Revenue Metrics
argenx SE and Amphastar Pharmaceuticals, Inc.: A Comprehensive Revenue Analysis
Alnylam Pharmaceuticals, Inc. and Amneal Pharmaceuticals, Inc.: A Comprehensive Revenue Analysis
Exelixis, Inc. and Amneal Pharmaceuticals, Inc.: A Comprehensive Revenue Analysis
Revenue Insights: Amneal Pharmaceuticals, Inc. and PTC Therapeutics, Inc. Performance Compared
Amneal Pharmaceuticals, Inc. vs MorphoSys AG: Examining Key Revenue Metrics
Revenue Showdown: Amneal Pharmaceuticals, Inc. vs Bausch Health Companies Inc.
Revenue Insights: Amneal Pharmaceuticals, Inc. and Novavax, Inc. Performance Compared
Amphastar Pharmaceuticals, Inc. or Travere Therapeutics, Inc.: Who Leads in Yearly Revenue?
Breaking Down Revenue Trends: Amphastar Pharmaceuticals, Inc. vs Celldex Therapeutics, Inc.
Revenue Showdown: Amphastar Pharmaceuticals, Inc. vs Novavax, Inc.